A major discovery of recent cancer genome-wide sequencing studies has been the identification of significant alterations in genes responsible for modifying chromatin structure 1 . ARID1A, which encodes a component of the SWI/SNF chromatin-remodeling complex, is among the genes that show the highest mutation rates across multiple cancer types 2 . The SWI/SNF complex remodels nucleosomes to modulate transcription, and its inactivation is thought to drive tumorigenesis by altering gene expression 3 . Notably, ARID1A is mutated in ~57% of ovarian clear cell carcinomas (OCCCs) 4,5 . ARID1A-mutated OCCCs are typically characterized by a lack of genomic instability 4, 6 . It has been suggested that perturbations in the regulation of epigenetic chromatin remodeling may be able to substitute for genomic instability 3 . These findings suggest that epigenetic mechanisms play a critical role in OCCC. Despite the prevalence of genetic mutations of ARID1A, a rational therapeutic approach to target cancers with ARID1A mutations has not yet been explored. EZH2, the catalytic subunit of polycomb repressive complex 2, silences gene expression through generation of the lysine 27 trimethylation mark on histone H3 (H3K27Me3) by its catalytic SET domain 7 . EZH2 is often overexpressed in OCCC 8 , and EZH2 gain-of-function mutations occur in hematopoietic malignancies such as diffuse large B cell lymphoma (DLBCL). Highly specific small molecule EZH2 inhibitors have been developed, and the response to EZH2 inhibitors often correlates with gain-of-function mutations in EZH2 (refs. 9-11). EZH2 inhibitors have entered clinical trials for the diseases mentioned above. Here we show that inhibition of EZH2 methyltransferase activity acts in a synthetic lethal manner in ARID1A-mutated cells. Our findings establish a new approach for targeting ARID1A mutation in cancer by using pharmacological inhibition of EZH2 methyltransferase activity.
a r t i c l e s
A major discovery of recent cancer genome-wide sequencing studies has been the identification of significant alterations in genes responsible for modifying chromatin structure 1 . ARID1A, which encodes a component of the SWI/SNF chromatin-remodeling complex, is among the genes that show the highest mutation rates across multiple cancer types 2 . The SWI/SNF complex remodels nucleosomes to modulate transcription, and its inactivation is thought to drive tumorigenesis by altering gene expression 3 . Notably, ARID1A is mutated in ~57% of ovarian clear cell carcinomas (OCCCs) 4, 5 . ARID1A-mutated OCCCs are typically characterized by a lack of genomic instability 4, 6 . It has been suggested that perturbations in the regulation of epigenetic chromatin remodeling may be able to substitute for genomic instability 3 . These findings suggest that epigenetic mechanisms play a critical role in OCCC. Despite the prevalence of genetic mutations of ARID1A, a rational therapeutic approach to target cancers with ARID1A mutations has not yet been explored. EZH2, the catalytic subunit of polycomb repressive complex 2, silences gene expression through generation of the lysine 27 trimethylation mark on histone H3 (H3K27Me3) by its catalytic SET domain 7 . EZH2 is often overexpressed in OCCC 8 , and EZH2 gain-of-function mutations occur in hematopoietic malignancies such as diffuse large B cell lymphoma (DLBCL). Highly specific small molecule EZH2 inhibitors have been developed, and the response to EZH2 inhibitors often correlates with gain-of-function mutations in EZH2 (refs. 9-11) . EZH2 inhibitors have entered clinical trials for the diseases mentioned above. Here we show that inhibition of EZH2 methyltransferase activity acts in a synthetic lethal manner in ARID1A-mutated cells. Our findings establish a new approach for targeting ARID1A mutation in cancer by using pharmacological inhibition of EZH2 methyltransferase activity.
RESULTS

EZH2 inhibitor is selective against ARID1A inactivation
As epigenetic mechanisms may play a critical role in ARID1A-mutated OCCC, we evaluated a panel of 15 commercially available small molecule inhibitors known to target epigenetic regulators to identify 'hits' that selectively inhibit the growth of ARID1A-inactivated cells (Supplementary Table 1 ). More than 90% of the ARID1A mutations observed in OCCC are frame-shift or nonsense mutations that result in a loss of ARID1A protein expression 4, 5, 12 . To mimic the loss of ARID1A protein expression caused by the vast majority of ARID1A mutations 4 and ensure the same genetic background, we performed the screen using ARID1A wild-type OCCC RMG1 cells with or without shRNA-mediated ARID1A knockdown (Fig. 1a,b and Supplementary Fig. 1a) . Following drug selection, cells were plated onto Matrigel and treated with one of 15 individual small molecules or vehicle control using the half-maximal inhibitory concentration (IC 50 ) (Supplementary Table 2) . We performed the screen in 3D cultures using Matrigel to more closely mimic the tumor microenvironment 13 . Notably, ARID1A knockdown itself did not significantly affect the growth of RMG1 cells in 3D culture (Supplementary Fig. 1b) . We based the dose of each small molecule on the previously established IC 50 value (Supplementary Table 2 ). Diameters of acini formed in 3D culture were measured as a surrogate for cell growth (Fig. 1c) . We identified three small molecule inhibitors that significantly a r t i c l e s 2 3 2 VOLUME 21 | NUMBER 3 | MARCH 2015 nature medicine (P ≤ 0.0001) and selectively inhibited the growth of ARID1A-knockdown cells compared to controls (Supplementary Table 1 ). GSK126 was the hit with the highest selectivity against ARID1A-knockdown cells (Fig. 1c,d and Supplementary Table 1) .
We observed a decrease in the size of acini with GSK126 using two individual shRNAs against ARID1A (shARID1As) ( Supplementary  Fig. 1c -e). GSK126 is a highly selective and potent small molecule inhibitor of EZH2 methyltransferase activity 9 . Notably, ARID1A knockdown did not alter the expression levels of EZH2 or H3K27Me3 (Fig. 1b) . 
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β-actin ARID1A mutation correlates with response to EZH2 inhibitor To validate the initial findings, we used four different ovarian cancer cell lines (TOV21G, OVISE, OVTOKO and SKOV3) with known ARID1A mutations 4, 6 . We observed a loss of ARID1A protein expression in these ARID1A-mutated cell lines (Fig. 2a) . There was a dose-dependent decrease in H3K27Me3 levels in ARID1A-mutated cells treated with GSK126 (Fig. 2b) ; a >95% reduction in H3K27Me3 levels was achieved with 5 µM GSK126 (Fig. 2b,c) . H3K9Me3, which is generated by different histone methyltransferases such as SUV39H1 and SETDB1 (ref. 14) , was not affected by GSK126 (Fig. 2b,c and Supplementary Fig. 1f-h ). GSK126 had no appreciable effect on EZH2 expression (Fig. 2b,c) 9 . ARID1A knockdown did not alter the dose-dependent reduction of H3K27Me3 levels by GSK126 (Supplementary Fig. 1h) .
Similar to what was observed in RMG1 cells, GSK126 treatment resulted in a significant decrease in 3D growth in ARID1A-knockdown KK and OVCA429 cells, two additional ARID1A wild-type OCCC cell lines ( Fig. 2d and Supplementary Fig. 1i-l) 15 . Furthermore, GSK126 significantly reduced the size of acini in all tested cell lines with ARID1A mutation, whereas the effects of GSK126 on the growth of ARID1A wild-type cell lines were not significant (Fig. 2e) . This was not due to the inability of GSK126 to inhibit EZH2 activity in ARID1A wild-type cells, as GSK126 was equally effective at decreasing H3K27Me3 levels in these cells ( Supplementary  Fig. 1j ). GSK126 treatment led to a significant reduction in cell number in ARID1A-mutated cells, but not in wild-type cells ( Fig. 2f  and Supplementary Fig. 1m ). Similar growth inhibition by GSK126 was observed in conventional 2D cultures as determined by cell counting (Supplementary Fig. 1n ). Growth inhibition of ARID1A-mutated cells also was observed with UNC1999 (ref. 16) , another EZH2 inhibitor with less selectivity than GSK126 ( Supplementary  Fig. 1o-q) .
To determine whether reintroducing wild-type ARID1A in ARID1A-mutated cells affects sensitivity to GSK126, we ectopically expressed wild-type ARID1A in ARID1A-mutated OVISE and TOV21G OCCC cells. As reported 15 , ARID1A restoration suppressed the growth of OCCC cells with ARID1A mutation (Fig. 2g,h ). GSK126 did not further reduce the size of acini in ARID1A-restored cells (Fig. 2h) . The IC 50 of GSK126 in ARID1A-mutated cells was ~267 nM (Fig. 2i) , which is comparable to what was previously observed in DLBCL with gain-of-function EZH2 mutation 9 . Restoration of wild-type ARID1A caused an ~16-fold increase in the IC 50 of GSK126 compared to controls (Fig. 2i) .
To establish that the observed effects were specifically due to inhibition of EZH2 activity, we knocked down EZH2 expression in ARID1A-mutated cells in combination with GSK126 treatment. Knockdown of EZH2 mimicked the growth inhibition induced by GSK126 treatment ( Supplementary Fig. 2a-f ). GSK126 did not have any substantial further effects on the growth of EZH2-knockdown ARID1A-mutated cells ( Supplementary Fig. 2d-f) . The observed growth inhibition caused by EZH2 knockdown was rescued by wild-type EZH2 but not by an enzymatically inactive SET domain-deleted EZH2 mutant ( Fig. 3a-d) 7 . This supports the notion that the observed growth inhibition depends upon EZH2 methyltransferase activity. a r t i c l e s EZH2 inhibition triggers apoptosis in ARID1A-mutated cells We stained acini for H3K27Me3 and the cell proliferation marker Ki67. GSK126 treatment significantly decreased amounts of H3K27Me3 and the percentage of Ki67-positive cells compared to controls (Fig. 3e-g ). GSK126 is known to induce apoptosis in DLBCL with gain-of-function EZH2 mutations 9 . To determine whether GSK126 triggers apoptosis in OCCC cells, we stained the acini for cleaved caspase 3, an apoptotic marker. Compared with controls, there was a significant increase in the percentage of cells positive for cleaved caspase 3 in GSK126-treated ARID1A-mutated cells (Fig. 3h-j) . Other apoptotic markers such as annexin V were also induced by GSK126 (Supplementary Fig. 3 ).
PIK3IP1 contributes to the observed synthetic lethality ARID1A and EZH2 belong to the SWI/SNF and polycomb complexes, respectively. The antagonistic roles of SWI/SNF and polycomb proteins in gene transcription were initially suggested on the basis of genetic studies in Drosophila 17 . We sought to determine whether the observed phenotypes are due to changes in gene expression. Microarray analysis of ARID1A-mutated OVISE cells treated with GSK126 or restored with wild-type ARID1A revealed a significant overlap in differentially regulated genes (2.4-fold enrichment, P = 5.9042 × 10 −11 for overlap in genes regulated by wild-type ARID1A restoration and GSK126 treatment) (Fig. 4a) . Known ARID1A target genes such as CDKN1A 15 were upregulated only by ARID1A restoration. Conversely, known EZH2 target genes such as TNSF10 (ref. 18) were upregulated only by GSK126 treatment. This suggests that the observed effects in EZH2 methyltransferase-inhibited ARID1A-mutated cells are mediated by a previously undefined set of genes that are commonly regulated by both ARID1A and EZH2.
To identify direct EZH2 and H3K27Me3 target genes in ARID1A-mutated cells, we cross-examined genes that were commonly upregulated by ARID1A restoration or GSK126 treatment with published data from chromatin immunoprecipitation followed by next-generation sequencing (ChIP-seq) of EZH2 and H3K27Me3 using ARID1A-mutated ovarian cancer cells 18 (Fig. 4a) . To identify biologically relevant genes, we cross-referenced the genes that were commonly upregulated by ARID1A restoration and GSK126 treatment with a publicly available OCCC gene expression database (Fig. 4a) that compares laser-capture microdissected (LCM) OCCC specimens with normal human ovarian surface epithelial (HOSE) cells 19 . H3K27Me3 silences gene expression 7 ; therefore, we focused on genes that were commonly upregulated by both GSK126 treatment and wild-type ARID1A restoration but downregulated in the LCM OCCC specimens compared to normal HOSE cells (Fig. 4a and  Supplementary Table 3) .
We chose the PI3K-interacting protein 1 gene (PIK3IP1) for validation for the following reasons: (1) PIK3IP1 negatively regulates npg PI3K-AKT signaling 20, 21 ; (2) PI3KCA is often mutated in OCCC, and mutations in PI3KCA and ARID1A often coexist in OCCC 22, 23 ; and (3) PIK3IP1 negatively regulates cell proliferation and promotes apoptosis 20 , the phenotypes observed in GSK126-treated ARID1A-mutated cells. There was a significant negative correlation between expression of EZH2 and PIK3IP1 in the microarray analysis of LCM specimens (Fig. 4b) 19 . Notably, PIK3IP1 was expressed at significantly lower levels in ARID1A-mutated than in wild-type OCCC cells 4 ( Fig. 4c) . Thus, we ectopically overexpressed PIK3IP1 and confirmed that PIK3IP1 inhibited PI3K-AKT signaling, suppressed cell growth and induced apoptosis in ARID1A-mutated cells ( Supplementary  Fig. 4a-d) . PIK3IP1 expression was significantly upregulated by both wild-type ARID1A restoration and GSK126 treatment in ARID1A-mutated cells (Fig. 4d and Supplementary Fig. 4e ). Supporting the notion that the observed upregulation of PIK3IP1 is due to inhibition of EZH2 methyltransferase activity by GSK126, PIK3IP1 upregulation induced by EZH2 knockdown in ARID1A-mutated cells was rescued by wild-type EZH2 but not by an enzymatically inactive SET domaindeleted EZH2 mutant (Supplementary Fig. 4f ). PIK3IP1 expression was not upregulated by GSK126 in ARID1A wild-type RMG1 cells (Supplementary Fig. 4g ), which correlated with the observation that GSK126 did not affect RMG1 cell growth (Fig. 2d) . ChIP analysis revealed a significant decrease in the association of H3K27Me3 with the PIK3IP1 gene promoter in GSK126-treated ARID1A-mutated cells compared with vehicle-treated controls (Fig. 4e) . In addition, ARID1A restoration caused a significant increase in the association of ARID1A with the PIK3IP1 gene promoter (Fig. 4f) . The association of core histone H3 with the PIK3IP1 gene promoter, assessed as a control, was not affected by either GSK126 treatment or ARID1A restoration (Supplementary Fig. 4h) . Association of BRG1, the catalytic subunit of the ARID1A-containing chromatin-remodeling complex, with the PIK3IP1 gene promoter was significantly enhanced by ARID1A restoration (Fig. 4f) . Consistent with this, there is evidence to suggest that ARID1A recruits the remodeling complex to its target genes 15, 24 . Interestingly, the association of EZH2 with the PIK3IP1 gene promoter was not decreased by either ARID1A restoration or GSK126 treatment (Fig. 4e,f) . Likewise, the association of H3K27Me3 with the PIK3IP1 gene promoter was not significantly decreased by ARID1A restoration (Fig. 4f) . The induction of PIK3IP1 by ARID1A restoration correlated with RNA polymerase II recruitment to its promoter (Fig. 4f) . Although EZH2 and H3K27Me3 are predominantly associated with silenced genes, they also localize to active genes 25 . However, these active genes are typically not regulated by EZH2 or H3K27Me3 (ref. 25) . Together, these data support a model whereby when both ARID1A and EZH2 are present at the PIK3IP1 gene promoter, ARID1A dominates over EZH2 and drives PIK3IP1 expression (Supplementary Fig. 4i) . Indeed, ARID1A restoration induced PIK3IP1 expression in ARID1A-mutated cells (Fig. 4d) , and the EZH2 inhibitor did not affect PIK3IP1 expression in ARID1A wild-type cells (Supplementary Fig. 4g ). When ARID1A was absent, EZH2 silenced PIK3IP1 expression, and when EZH2 methyltransferase activity was subsequently suppressed, PIK3IP1 was expressed (Supplementary Fig. 4i) . Consistent with this, there was no additional increase in PIK3IP1 expression in ARID1A-mutated cells treated with a combination of GSK126 and wild-type ARID1A restoration (Fig. 4g) . ChIP analysis in ARID1A wild-type cells revealed that both ARID1A and EZH2 are associated with the PIK3IP1 gene promoter (Fig. 4h) . ARID1A knockdown in ARID1A wild-type cells decreased the association of ARID1A with the PIK3IP1 gene promoter (Fig. 4h) , which correlated with a decrease in RNA polymerase II's association with the PIK3IP1 gene promoter (Fig. 4h) and suppression of PIK3IP1 expression ( Fig. 4i and  Supplementary Fig. 4j ). There was no decrease in the association of either EZH2 or H3K27Me3 with the PIK3IP1 gene promoter after ARID1A knockdown (Fig. 4h) . Indeed, treatment of ARID1A-knockdown cells with GSK126 led to the restoration of PIK3IP1 expression in ARID1A wild-type cells (Fig. 4i) .
To determine whether genetic knockdown of PIK3IP1 rescues the growth inhibition observed in GSK126-treated ARID1A-mutated cells, we used two individual shRNAs against PIK3IP1 that knocked down its expression. Knockdown of PIK3IP1 significantly rescued the growth suppression induced by GSK126 in ARID1A-mutated cells (Fig. 5a-d and Supplementary Fig. 5a,b) . Upregulation of cleaved caspase 3 induced by GSK126 in ARID1A-mutated cells was also significantly suppressed by PIK3IP1 knockdown (Fig. 5e,f and Supplementary Fig. 5c,d) .
As PIK3IP1 suppresses PI3K-AKT signaling ( Supplementary  Fig. 4a ) and contributed to the observed effects of GSK126 in ARID1A-mutated cells (Fig. 5) , we sought to determine whether PI3K-AKT signaling affects the sensitivity of ARID1A-mutated cells to GSK126. We ectopically expressed a constitutively active myristoylated PI3KCA mutant (myrPI3KCA) in an ARID1A-mutated OVTOKO cell line that does not have mutated PI3KCA 6 to increase PI3K-AKT signaling (Fig. 5g) . Indeed, the PI3KCA mutant further enhanced the observed growth inhibition by GSK126 (Fig. 5h,i) . This supports the notion that the effects of EZH2 inhibition in ARID1A-mutated cells are due to increased expression of PIK3IP1, an inhibitor of PI3K activity. Consequently, increased PI3K activity results in increased sensitivity to EZH2 inhibition, which results in more growth inhibition.
EZH2 inhibitor causes regression of ARID1A-mutated tumors GSK126 is a specific EZH2 inhibitor that is well tolerated in immunocompromised mice 9 . We orthotopically injected luciferase-expressing ARID1A-mutated OVISE cells into the bursa sac covering the ovary in immunocompromised female mice. The injected cells were allowed to grow for 1 week to establish tumors. We randomly assigned mice into two groups (n = 5 mice per group) and treated mice daily with vehicle control or GSK126 (50 mg/kg) by intraperitoneal injection for an additional 3 weeks 9 . GSK126 treatment caused regression of the orthotopically transplanted ARID1A-mutated OVISE cells (Fig. 6a,b) . At necropsy, we measured the tumor size and found that GSK126 treatment significantly decreased the size of the orthotopically xenografted tumors compared with controls (Fig. 6c) . Similarly, GSK126 treatment (50 mg/kg daily for 2 weeks) caused regression of orthotopically xenografted ARID1A-mutated TOV21G tumors that had been established over 4 weeks (Supplementary Fig. 6a ).
In contrast, GSK126 treatment did not significantly affect the size of orthotopically xenografted ARID1A wild-type RMG1 tumors (Supplementary Fig. 6b) . We sought to determine the effects of GSK126 on another clinical feature of ovarian cancer 26 , the dissemination of ARID1A-mutated OCCC cells, in an intraperitoneal xenograft model. We injected ARID1A-mutated OVISE cells into the mouse intraperitoneal cavity. The injected tumor cells were allowed to grow for 4 d, and the mice were then randomized into two groups (n = 6 mice per group). Mice were treated daily with GSK126 (50 mg/kg) or vehicle control via intraperitoneal injection. Compared with controls, GSK126 significantly reduced the number of tumor nodules within the peritoneal cavity after 3 weeks of treatment ( Fig. 6d and Supplementary Fig. 6c) .
Immunohistochemical analysis of ARID1A-mutated tumors treated with GSK126 or vehicle controls revealed that H3K27Me3 staining was decreased by GSK126, whereas GSK126 did not weaken EZH2 staining (Fig. 6e,f) . Furthermore, GSK126 treatment decreased the expression of Ki67 (Fig. 6e,f) . There was an increase in PIK3IP1 staining and a decrease in phospho-AKT staining in GSK126-treated tumors (Fig. 6e,f) . Consistent with this, the apoptotic marker cleaved caspase 3 was induced by GSK126 (Fig. 6e,f) . In ARID1A wild-type tumors, although GSK126 decreased H3K27Me3 staining ( Supplementary  Fig. 6d) , it did not affect the expression of Ki67, PIK3IP1, phospho-AKT or cleaved caspase 3 (Supplementary Fig. 6d ).
DISCUSSION
The EZH2 inhibitor selectively suppressed the growth of ARID1A-mutated cells. This was not due to either changes in EZH2 expression or an inability of the EZH2 inhibitor to suppress the enzymatic activity of EZH2 in ARID1A wild-type cells, as GSK126 was consistently effective in decreasing H3K27Me3 levels regardless of ARID1A mutation status (Fig. 2) . Similarly, in DLBCL, the response to EZH2 inhibitors often correlates with gain-of-function mutations in EZH2 (refs. 9-11), despite the fact that EZH2 inhibitors are equally effective at reducing H3K27Me3 levels in cells with wild-type EZH2. A recent study shows that ARID1B is a specific vulnerability in ARID1A-mutated cancers 27 , further highlighting the potential of synthetic lethal strategies for ARID1A mutation in cancer.
ARID1A and EZH2 are antagonistic in regulating PIK3IP1 expression (Fig. 4) . We were unable to perform ARID1A ChIP-seq analysis because of the lack of a suitable anti-ARID1A antibody; regardless, we successfully identified PIK3IP1 as the ARID1A-EZH2 target gene contributing to the observed synthetic lethality (Fig. 5) . In rhabdoid tumors, a loss of SNF5, a core subunit of SWI/SNF, directly upregulates EZH2 (ref. 28) . The survival of SNF5-deficient cancer cells depends on the upregulated EZH2, and these cancer cells are sensitive to EZH2 inhibition 28, 29 . Here, ARID1A knockdown did not affect EZH2 expression, but it did sensitize cells to EZH2 inhibition (Figs. 1b,c and 2d and Supplementary Fig. 1i-l) . Conversely, the restoration of wild-type ARID1A in ARID1A-mutated cells conferred resistance to the EZH2 inhibitor, also without changing EZH2 expression (Fig. 2g) . Thus, the antagonism between EZH2 and ARID1A occurs at a functional level (Fig. 6g and Supplementary Fig. 4i ).
Our studies demonstrate that targeting EZH2 methyltransferase activity through the use of EZH2 inhibitors in ARID1A-mutated cells represents a novel synthetic lethal therapeutic strategy. Given that mutation and loss of expression of ARID1A and genetic alterations in other subunits of ATP-dependent chromatin remodeling complexes are observed at a high frequency in many cancer types 1, 30 , we expect our finding to have far-reaching implications for future epigenetic therapeutic strategies.
METHODS
Methods and any associated references are available in the online version of the paper.
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Cell lines and 3D culture conditions. OVISE, TOV21G, RMG1 and OVTOKO cell lines were all obtained from the Japanese Collection of Research Bioresources. The SKOV3 cell line was obtained from the American Type Culture Collection. OVCA429 and KK cell lines were obtained from I.-M. Shih. All cell lines were cultured according to instructions and in 3D conditions using Matrigel, unless otherwise specified. All cell lines were used within 6 months of culture after they were received, but they were not tested. The 3D culture procedure was adapted from previously published methods 31 and used growth-factor-reduced Matrigel (BD Biosciences). In the 3D culture models, GSK126 treatment was started at the time of assay setup. Briefly, a single cell suspension was plated in eight-well chambers covered with Matrigel. Matrigel media with either vehicle control (DMSO) or drug was changed every 4 d, and cells were grown for 12 d. Each of the experiments was performed in duplicate in three independent experimental repeats.
Reagents and antibodies. Small molecules used in the screen were all obtained from the Molecular Screening Facility at the Wistar Institute. GSK126 was obtained from Xcess Biosciences and Active Biochem. UNC1999 was obtained from Selleckchem. The following antibodies from the indicated suppliers were used: anti-EZH2 (BD Bioscience, cat. no. 612666, 1:1,000), anti-EZH2 (Cell Signaling, cat. no. 5246, 1:100), anti-ARID1A (Sigma, cat. no. HPA005456, 1:1,000), anti-H3K27Me3 (Cell Signaling, cat. no. 9733, 1:1,000), anti-β-actin (Sigma, cat. no. A5441, 1:10,000), anti-ARID1A (Santa Cruz, cat. no. sc-32761, 1:500), anti-Ki67 (Cell Signaling, cat. no. 9449, 1:1,000), anti-PIK3IP1 (Santa Cruz, cat. no. sc-86785, 1:500), anti-histone H3 (Millipore, cat. no. 06-755, 1:1,000), anti-GAPDH (Millipore, cat. no. MAB374, 1:10,000), anti-cleaved caspase 3 (Cell Signaling, cat. no. 9661, 1:10,000), anti-PI3K (p110alpha) (Cell Signaling, cat. no. 4255, 1:1,000), anti-pAKT (T308, Cell Signaling, cat. no. 13038, 1:1,000), anti-AKT (Cell Signaling, cat. no. 9272, 1:1,000) and anti-H3K9Me3 (Abcam, cat. no. ab8898, 1:1,000). pBabe-Myr-PIK3CA143V plasmid was obtained from Addgene. pBabe-EZH2, pBabe-EZH2 ∆SET and pQCXIP-PIK3IP1 plasmids were generated via standard molecular cloning protocols, and details are available upon request.
Lentivirus infection. pLenti-CMV-Puro-Luciferase was obtained from Addgene. pLKO.1-shARID1As (TRCN0000059090 and TRCN0000059089), pLKO.1-shEZH2 (TRCN0000040073), and pLKO.1-shPIK3IP1 (1, TRCN0000133982; 2, TRCN0000135363; and 3, TRCN0000138560) were obtained from the Molecular Screening Facility at the Wistar Institute. Lentivirus was packaged using the Virapower Kit from Invitrogen according to the manufacturer's instructions as described previously 8, 32, 33 .
Microarray, database and bioinformatics. ARID1A-mutated OVISE cells expressing inducible wild-type ARID1A 15 were plated on Matrigel and treated with DSMO, 1 µg/mL doxycycline to induce wild-type ARID1A expression, or with 5 µM GSK126. Cells were recovered from 3D culture, and RNA was extracted with Trizol (Invitrogen) and subsequently cleaned and DNase-treated using RNeasy columns (Qiagen). Eukaryote total RNA nano Bioanalyzer (Agilent) assay was used to confirm the quality of the RNA, and all RNA used for subsequent steps had an RNA integrity number >8.6. cDNA made from the RNA was hybridized to Illumina Bead Array HumanHT-12 v4 by the Wistar Genomics Facility (whole human genome). Images were analyzed and expression changes were evaluated in Illumina GenomeStudio. Illumina GenomeStudio was also used to export expression levels and detect P values for each probe of each sample. Signal-intensity data were quantile normalized, and probes that showed an insignificant detection P value (P > 0.05) in all samples were removed from further analysis. Pair-wise group comparisons were done using paired SAM test 34 , and correction for multiple testing to estimate the false discovery rate (FDR) was done with the procedure described by Storey and Tibshirani 35 . Differentially expressed genes in the ARID1A-restored sample were overlapped with differentially expressed genes in the GSK126 sample, and the significance of the overlap was calculated using the hypergeometric test. We used statistical methods for defining significantly changed genes with an FDR of 10% as a cutoff plus P < 0.05 for overlap. All microarray data can be found at the Gene Expression Omnibus (GEO) database (GEO accession number: GSE54979).
Gene-expression microarray data sets for 10 cases of laser-capture and microdissected ovarian clear cell carcinomas and 10 individual isolations of normal human ovarian surface epithelial cells were obtained from GEO (http:// www.ncbi.nlm.nih.gov/geo/) (GEO accession number: GSE29450) 19 . EZH2-H3K27Me3 ChIP-seq in ARID1A-mutated ovarian cancer SKOV3 cells was obtained through published data 18 . RNA-seq data for ARID1A wild-type or mutated OCCC specimens were obtained from the European Genome-Phenome Archive 4 . Only samples with comparable 50-bp length-read data were analyzed. Sample CCC66 was not considered for analysis because of the low number of reads (<50% of the median number of reads across all samples). Bowtie2 (ref. 36) was used for alignment against the hg19 version of the human genome, and TopHat2 (ref. 37 ) was used to estimate RPKM expression values for each gene transcript in each sample using transcript information from the UCSC database. ARID1A-positive samples without mutation were assigned to the ARID1A wild-type group (n = 5: CCC67, CCC69, CCC71, CCC72 and CCC73), and ARID1A-negative samples with mutation were assigned to the ARID1A-mutated group (n = 4: CCC02, CCC04, CCC14 and CCC14). A two-tailed unpaired t-test was used to compare the two groups.
Annexin V staining for detecting apoptotic cells (Guava assay).
Phosphatidylserine externalization was detected using an annexin V staining kit (Millipore) according to the manufacturer's instructions. Annexin V-positive cells were detected using the Guava System and analyzed with the Guava Nexin software module (Millipore).
Reverse-transcriptase quantitative PCR. RNA was extracted from cells with Trizol (Life Technologies) and DNase-treated using RNeasy columns (Qiagen). The expression of mRNA levels for PIK3IP1 (forward, 5′-GCTAGGAGGAACTACCACTTTG-3′; reverse, 5′-GATGGACAAGGAGC ACTGTTA-3′), EZH2 ORF (forward, 5′-GACGGCTTCCCAATAACAGTA-3′; reverse, 5′-AGTGCCAATGAGGACTCTAAA-3′) and EZH2 3′UTR (forward, 5′-AATCCCTTGACCTCTGAAAC-3′; reverse, 5′-ACTGGTA CAAAACACTTTGC-3′) was determined using SYBR green iScript (Bio-Rad) master mix on a Bio-Rad Chromo4 machine. β-2-microglobulin was used as an internal control.
Immunofluorescence and immunohistochemical staining. Immunofluorescence was performed on day 8 or 12 as indicated in Figs. 3e, 3h and 5e by fixing samples in 2% paraformaldehyde and permeabilizing in 2% paraformaldehyde with 0.5% Triton-X. Samples were incubated with primary antibodies for 2 h at room temperature and with highly cross-absorbed secondary antibodies (Invitrogen) for 1 h at room temperature and mounted with ProLong antifade reagent (Invitrogen). Immunostained acini were then imaged using a Leica confocal microscope. Immunohistochemical staining was performed as described previously 38 on consecutive sections from xenografted tumors dissected from control or GSK126-treated immunocompromised nude female mice.
Intraperitoneal and intrabursal orthotopic xenograft models in vivo. The protocols were approved by the Institutional Animal Care and Use Committee of the Wistar Institute. For the intraperitoneal model, 3 × 10 6 OVISE cells were injected intraperitoneally into 6-8-week-old female immunocompromised nude mice. On day 4 after injection, mice were randomized into vehicle control (captisol) and GSK126 treatment groups at 50 mg/kg daily for an additional 26 d (n = 6 mice per group). At the end of experiments (day 30), mice were killed, and the formation of tumor nodules in the peritoneal cavity was examined. Intrabursal orthotopic xenograft was performed as described previously 38, 39 . Briefly, 1 × 10 6 luciferase-expressing ARID1A-mutated OVISE cells were unilaterally injected into the ovarian bursa sac of 6-8-week-old female immunocompromised nude mice (n = 5 per group). For in vivo experiments, the sample size of five mice per group was determined on the basis of data from in vitro experiments. The observed effect size (defined as the difference of means divided by the sd) was as large as 2.9 in our in vitro data. To be conservative, for in vivo experiments, we expected to see an effect size of at least 2.0. In order to have more than 80% power to detect an effect size of 2.0 or larger at a two-sided statistical significance level, five mice per group would be required.
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The in vivo experimental data reflect an effect size of 2.7, which is consistent with our hypothesis. One week after injection of OVISE cells, we visualized tumors by injecting luciferin (IP; 4 mg per mouse) resuspended in PBS and imaged them with an IVIS Spectrum imaging system. The mice were then randomized into two groups based on luciferase activity and treated with vehicle control (captisol) or GSK126 at 50 mg/kg daily for an additional 3 weeks, during which time they were imaged weekly for luciferase activity. Images were analyzed using Live Imaging 4.0 software. Imaging analysis was performed blindly but not randomly. At the end of the experiments (day 30), tumors were surgically dissected, and the sizes of ovaries from both the injected side and the contralateral side were measured. We calculated the tumor size by subtracting the size of the control-side ovary from that of ovary on the side injected with tumor cell to limit variations among different mice. For intrabursal orthotopic xenografts using ARID1A-mutated TOV21G or ARID1A wild-type RMG1 cells, the same procedure was used, except tumors were established for 4 weeks before the randomized mice were treated with vehicle control (captisol) or GSK126 at 50 mg/kg daily for an additional 2 weeks.
Chromatin immunoprecipitation. ChIP was performed as previously described 33 . The following antibodies were used to perform ChIP: anti-H3K27Me3 (Cell Signaling, cat. no. 9733), anti-ARID1A (Santa Cruz, cat. no. sc-32761), anti-BRG1 (Santa Cruz, cat. no. sc-10768), anti-RNA polymerase II (Santa Cruz, cat. no. sc-899) and anti-EZH2 (Cell Signaling, cat. no. 5246). Isotype-matched immunoglobulin G was used as a negative control. ChIP DNA was analyzed by quantitative PCR against the promoter of the human PIK3IP1 gene using the following primers: forward, 5′-CACATTGA-GCTGGTGTTTGTT-3′; and reverse, 5′-CCATTGCCACTTCAAAGAGTTT-3′.
Statistical analysis. Statistical analyses were performed using GraphPad Prism 5 (GraphPad) for Mac. Quantitative data are expressed as mean ± sem unless otherwise stated. Spearman's test was used to measure statistical correlation. For all statistical analyses, the level of significance was set at 0.05.
